Alternatives to Lagevrio If You Can't Fill Your Prescription

You've been prescribed Lagevrio (molnupiravir) for COVID-19, but your pharmacy doesn't have it. You're running out of time — treatment must start within five days of symptoms. The good news: you're not out of options. Here's what you and your doctor can consider.

A Quick Note: Why Was Lagevrio Prescribed Instead of Paxlovid?

Lagevrio is typically prescribed when Paxlovid (the preferred first-line COVID antiviral) is either unavailable or not appropriate for a specific patient — usually due to significant drug interactions. Understanding why your doctor chose Lagevrio matters when considering alternatives, because some alternatives may face the same prescribing barriers.

Alternative 1: Paxlovid (Nirmatrelvir/Ritonavir)

Paxlovid is the first-line oral antiviral for COVID-19. Clinical trials showed approximately an 89% reduction in hospitalization and death risk among high-risk adults when taken within 5 days of symptom onset — significantly more effective than Lagevrio's approximately 30% reduction. If you were prescribed Lagevrio because of drug interactions, your doctor will need to review your medication list before switching to Paxlovid.

Key facts about Paxlovid:

FDA-approved (full approval May 2023)

Oral pill — 3 pills twice daily for 5 days

Significant drug interactions due to ritonavir component — requires medication review

Not recommended for severe renal impairment (eGFR < 30 mL/min)

Alternative 2: Remdesivir (Veklury)

Remdesivir (brand name Veklury) is an FDA-approved antiviral made by Gilead Sciences. It works by blocking the RNA polymerase enzyme the SARS-CoV-2 virus uses to replicate. Unlike Paxlovid and Lagevrio, remdesivir is given as an intravenous (IV) infusion — typically three consecutive daily infusions over three days at an outpatient infusion center.

Key facts about Remdesivir:

FDA-approved for COVID-19 treatment

Strong evidence base from clinical trials

Requires three separate infusion visits — less convenient than oral antivirals

Best for patients who cannot take oral antivirals or have significant drug interactions

Alternative 3: Supportive Care + Close Monitoring

For patients who cannot access any antiviral treatment, supportive care remains important. This includes rest, hydration, acetaminophen or ibuprofen for fever and pain, and close monitoring for warning signs of worsening disease. Patients at high risk should have a clear action plan with their provider for when to seek emergency care. This is not a preferred approach — antiviral treatment is always better if accessible — but it is a reality for some patients.

Comparing the Options

Here's a quick side-by-side comparison:

Lagevrio (molnupiravir): Oral, 5-day course, EUA-only, ~30% risk reduction, minimal drug interactions, not for pregnancy or under-18

Paxlovid (nirmatrelvir/ritonavir): Oral, 5-day course, FDA-approved, ~89% risk reduction, significant drug interactions, renal dose adjustment needed

Remdesivir (Veklury): IV infusion, 3-day course, FDA-approved, strong evidence, requires infusion center access

Before You Switch: Try to Find Lagevrio First

If your doctor prescribed Lagevrio for good reason (e.g., drug interactions prevent Paxlovid), switching to Paxlovid may not be safe. Before giving up, use medfinder to check pharmacies near you. medfinder contacts pharmacies on your behalf to find which ones have Lagevrio in stock, saving you time during your critical treatment window.

Act Quickly — The 5-Day Window Is Not Flexible

All COVID antivirals — Lagevrio, Paxlovid, and Remdesivir — must be started within five days of symptom onset to be most effective. Don't spend multiple days searching before calling your prescriber to discuss alternatives. Speed matters. For the latest on availability, see our Lagevrio shortage update.